Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.62 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 4/20 | 0.45 |
| ▸ | NOS3 | P29474 | 3/20 | 0.45 |
| ▸ | NOS1 | P29475 | 3/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | GLUL | P15104 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL508142 | 1.00 | OTC (0.62) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL11738414 | 1.00 | OTC (0.62) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL11738420 | 1.00 | OTC (0.62) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL29089653 | 0.98 | OTC (0.60) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL19622767 | 0.98 | OTC (0.60) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL11670283 | 0.98 | OTC (0.60) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL11670280 | 0.98 | OTC (0.60) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL29038535 | 0.98 | OTC (0.60) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL20531891 | 0.98 | OTC (0.60) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL29234001 | 0.98 | OTC (0.60) | OTCDDAH1NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-2384740-B1 | Oral care product and methods of use and manufacture thereof | COLGATE PALMOLIVE CO (US) | 2025-05-07 | — | — | EP | claimed |
| EP-4539881-A1 | ANTI-COMPLEMENT C1S ANTIBODY FORMULATION | Bioverativ USA Inc. (US) | 2025-04-23 | — | — | EP | claimed |
| CN-119698296-A | Anti-complement C1S antibody formulations | 美国比奥维拉迪维股份有限公司 | 2025-03-25 | — | — | CN | claimed |
| EP-3547995-B1 | COMPOSITION FOR PROVIDING HIGH LIFT AND COLOR DEPOSIT | HENKEL AG & CO KGAA (DE) | 2024-08-14 | — | — | EP | claimed |
| CN-118436804-A | Cerium oxide-zirconium oxide and arginine nanocomposite drug targeting arterial vulnerable plaque microenvironment and preparation and application thereof | 上海市第八人民医院 | 2024-08-06 | — | — | CN | claimed |
| CN-118215488-A | Phosphate and arginine containing compositions and delivery of such compositions for virulence inhibition | 舒万诺知识产权公司 | 2024-06-18 | — | — | CN | claimed |
| US-20240130956-A1 | HAIR COSMETIC COMPOSITION | KAO CORPORATION (JP) | 2024-04-25 | — | — | US | claimed |
| US-20240117021-A1 | ANTI-COMPLEMENT C1S ANTIBODY FORMULATION | BIOVERATIV USA INC. (US) | 2024-04-11 | — | — | US | claimed |
| WO-2023245048-A1 | ANTI-COMPLEMENT C1S ANTIBODY FORMULATION | BIOVERATIV USA INC. (US) | 2023-12-21 | — | — | WO | claimed |
| CN-1227483-A | Anti-caries oral compositions | UNIV NEW YORK STATE RES FOUND (US) | 1999-09-01 | — | — | CN | claimed |
| US-5919443-A | GRANULOCYTE COLONY STIMULATING FACTOR | BOEHRINGER MANHEIM GMBH (DE) | 1999-07-06 | — | — | US | claimed |
| US-5919757-A | GRANULOCYTE COLONY STIMULATING FACTOR MIXTURE CONTAININGBUFFER AND SURFACTANT | BOEHRINGER MANNHEIM GMBH (DE) | 1999-07-06 | — | — | US | claimed |
| EP-0567433-B2 | Orally-ingestible nutrition compositions having improved palatability | NOVARTIS NUTRITION AG (CH) | 1998-11-25 | — | — | EP | claimed |
| US-5780039-A | COMPRISING NONBITTER, ACIDIC AMINE SALT OF PEPTIDE | NOVARTIS NUTRITION AG (CH) | 1998-07-14 | — | — | US | claimed |
| EP-0674524-B1 | STABLE LYOPHILIZED PHARMACEUTICAL PREPARATIONS G-CSF | BOEHRINGER MANNHEIM GMBH (DE) | 1998-04-15 | — | — | EP | claimed |
| EP-0123037-B1 | PROCESS FOR PREPARING AN ADHESIVE, PREFERABLY FOR GLUEING TOGETHER CELLULOSE-CONTAINING MATERIALS AND TEXTILES | Nyugatmagyarorszagi Fagazdasagi Kombinat (HU) | 1988-04-20 | — | — | EP | claimed |
| EP-0260137-A2 | Assay method using novel NAD synthetase and a process for production of the enzyme | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1988-03-16 | — | — | EP | claimed |
| US-4686211-A | Medical composition for external application | KAO CORPORATION (JP) | 1987-08-11 | — | — | US | claimed |
| US-3997659-A | PEROXIDE AND PEROXYDISULFATE OR PEROXYDIPHOSPHATE | THE PROCTER & GAMBLE COMPANY (US) | 1976-12-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240130956-A1 | HAIR COSMETIC COMPOSITION | PHOSPHO1, ODC1, H1-0 | OTC 82/4885DDAH1 1296/4885NOS2 957/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | OTC 3847/4885DDAH1 3015/4885NOS2 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.